International guideline changes and the incidence of infective endocarditis: a systematic review

Omeair Khan, Ahmed Mohamed Abdel Shafi, Adam Timmis

ABSTRACT
The objective of this study was to determine the impact on incident infective endocarditis (IE) of guideline recommendations to restrict indications for antibiotic prophylaxis. We conducted a systematic review according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline. PubMed and EMBASE databases were searched for articles published between 2007 and 2015 using mesh terms relevant to the research question. Included were English language articles published after 2009 that provided estimates of IE incidence before-and-after major international guideline changes. Seven studies were identified: 1 conducted in France, 4 in the USA and 2 in the UK. Only 1 study reported an increase in the rate of incident IE following guideline modification, and the remainder showed no change in upward (2 studies) or downward (4 studies) incidence trends. Study quality was generally poor for answering the question posed in this review, with serious risk of bias related to diagnostic ascertainment and unavailability of population risk data to adjust the incidence estimates. Moreover, the studies were often small, and relevant bacteriological data were not always available. Only 2 reported changes in antibiotic prescriptions, but these data were not linked to health records making it impossible to determine causal relations to changes in incident IE. The studies in this review were heterogenous in their design and variably limited by study size, duration of follow-up, diagnostic ascertainment, and absence of relevant prescription and bacteriological data. The studies were inconsistent in their conclusions and it remains uncertain what, if any, has been the impact of antibiotic prophylaxis guideline changes on the incidence of IE.

INTRODUCTION
Infective endocarditis (IE) is a relatively rare disorder with an estimated incidence of 3–10 cases per 100 000 per year.\(^1\) Despite diagnostic and therapeutic advances, prognosis remains poor, as reflected by hospital mortality of about 22%, rising to 40% at 5 years.\(^2\)\(^,\)\(^3\) Morbidity rates are also high; 50% of patients require operative management in the acute phase of the disease, often with ongoing consequences for quality of life.\(^4\)\(^,\)\(^5\) The substantial risk associated with IE has driven recommendations for antibiotic prophylaxis in high-risk subgroups, particularly those with valvular heart disease and other structural cardiac disorders.

Ever since the 1950s when the large-scale commercial production of penicillin was established, the American Heart Association (AHA) has advocated antibiotic prophylaxis in subgroups of patients undergoing invasive procedures, including dental extraction and certain gastrointestinal and genitourinary procedures, that are likely to cause secondary bacteraemia.\(^6\) Secondary bacteraemia in relation to these procedures is well documented but a causal relationship with IE has never been established in randomised trials or case–control studies.\(^7\)\(^,\)\(^8\) Despite this, antibiotic prophylaxis has remained a central component of management in at-risk individuals for over 50 years.

In 2002, innovative guidelines in France challenged accepted practice by suggesting restriction of prophylaxis against IE to patients with the highest ratio of benefit to individual and collective risk while emphasising the importance of general and oral hygiene in populations at risk.\(^9\) In 2007, the AHA—followed in 2009 by the European Society of Cardiology (ESC)—withdrew recommendations for antibiotic prophylaxis in all but the highest risk individuals such as those with previous IE, prosthetic heart valves or immunodeficiency disorders.\(^10\)\(^,\)\(^11\) The UK National Institute for Health and Care Excellence (NICE) made the yet more radical recommendation for complete cessation of antibiotic prophylaxis in all individuals regardless of risk.\(^12\) These new guideline recommendations, summarised in table 1, broke with a long-established principle of care and caused deep concern among many clinicians who cited historical, often small studies in questioning whether
the recommendation was evidence based and whether it was safe for patients. NICE was unrepentant arguing that the absence of an evidence base was precisely why the need for antibiotic prophylaxis had been questioned and that the harms of anaphylaxis through wide-scale application of antibiotic prophylaxis were likely to exceed any potential benefits of IE prevention.

The change in guidance has prompted studies internationally to analyse the impact on the incidence of IE. Findings have been inconsistent and there remains considerable uncertainty about the epidemiological consequences of the new guideline recommendations. In order to help resolve this uncertainty, we have undertaken a systematic review of studies to determine whether the change in guidance has been associated with an increase in the incidence of IE. Study characteristics of interest were defined as follows:

- **Population**: healthy population cohorts;
- **Intervention**: modified guideline recommendations for antibiotic prophylaxis against IE;
- **Comparisons**: rate of incident IE before-and-after guideline modification;
- **Study design**: observational cohort studies.

## METHODS

The systematic review was conducted using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline.15

### Eligibility criteria

Studies were included based on a methodological approach taking into consideration the type of study, when the study was published, the study population and whether the study provided estimates of IE diagnostic rates before-and-after changes to guideline recommendations for antibiotic prophylaxis. Specific inclusion criteria were for studies with the following characteristics:

- Publication in the English language;
- Publication after the change in AHA antibiotic prophylaxis guidelines in 2007;
- Provision of estimates of IE incidence in the study population before the change of antibiotic prophylaxis guidelines and again for at least 1 year afterwards.

### Data synthesis

After selection of the relevant studies, the data were extracted by one author into a table with predefined variables to summarise all the key points with respect to each of the included studies.

### Quality of the evidence

Individual studies included in the review had a quality control assessment against modified STROBE checklist criteria for observational studies, particularly directed at assessing sources of bias.15

### Data synthesis

No formal quantitative pooling of results was performed based on the heterogeneity of the studies in general and

### Table 1

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dental procedures involving manipulation of gingival tissue in high-risk patients</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Prosthetic valve</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Previous IE</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Congenital heart disease</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Cardiac transplantation with valvular heart disease</td>
<td>Not specified</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>Optional</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

AHA, American Heart Association; ESC, European Society of Cardiology; IE, infective endocarditis; NICE, National Institute for Health and Care Excellence.
the data in particular. Synthesis of the data was performed qualitatively, and clinical implications are drawn.

RESULTS
Study selection
Of 2292 studies identified in the initial database search, 1305 were excluded after applying restrictions (figure 1). After reviewing the title, abstract and key words, a further 969 studies were excluded. The remaining 18 studies were subjected to full-text review which led to exclusion of another 11, either because IE incidence or trends in incidence were not reported or because the main focus of the articles was on prescription trends or clinicians’ perspectives. The remaining seven studies\textsuperscript{16–22} fulfilled all inclusion criteria and are the subject of this review (table 1).

Study characteristics
The characteristics of the seven relevant studies are summarised in table 2 where each is allocated a study number. All were observational. Study 2 was conducted in France where the French guideline was implemented in 2002, and studies 3, 4, 6 and 7 were conducted in the USA where AHA guidelines were implemented in 2007. Study 1 was conducted in the UK where NICE guidelines were implemented in 2008 but, because follow-up was limited to 2 years, study 5 was later conducted providing an additional follow-up. In none of the studies were detailed descriptors of the denominator populations available. Studies 1, 3, 5 and 7 were very large recruiting between 19,804 and 457,052 patients with IE but the remainder was smaller, study 6 from the USA recruiting just 27 patients. Study 2 from France compared rates of IE in discrete cohorts surveyed in 12-month periods before (1991 and 1999) and after (2008) the date of guideline change. The remaining six studies analysed trends in diagnostic rates across periods of 10–14 years that ‘bridged’ the dates of guideline implementation. Only studies 1 and 5 from the UK provided data on antibiotic prescriptions before-and-after guideline implementation. Data on bacteriological diagnosis were provided in all but one of the studies but, apart from study 6, this was variably incomplete.

Diagnostic ascertainment
Study 2 collected cases of IE from participating clinicians with separate bacteriological confirmation and independent case validation by application of modified von Reyn and Duke criteria. Diagnostic ascertainment was also robust in study 6 which included patients with a definitive diagnosis of IE by Duke criteria. In all other studies, inclusion was based on the International Classification of Disease coding in the data source without further validation.

Data sources
Patients with IE were identified in national registries in UK studies 1 and 5, in Medicare, voluntary or bespoke data collections in US studies 3, 4, 6 and 7 and in physician surveys in French study 2. In three studies, no age criteria were applied but in studies 2, 3, 4 and 6, the study populations were selected by age: study 4 recruiting only patients aged <18, study 3 Medicare beneficiaries aged >65, and studies 2 and 6 adults aged >20 and >18, respectively.

Study quality
Selected quality indicators from the STROBE checklist relevant to the studies included in this review are shown
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Data source</th>
<th>Population</th>
<th>Population size</th>
<th>Cases of IE</th>
<th>Analysis</th>
<th>Date of guideline</th>
<th>IE incidence trends</th>
<th>Change in IE incidence after guideline change</th>
<th>Prescription and bacteriological data</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Duval et al</td>
<td>France</td>
<td>Three 1-year surveys in three French regions</td>
<td>Age &gt;20</td>
<td>11 million</td>
<td>993</td>
<td>Age-standardised and sex-standardised IE annual incidence trends</td>
<td>2002 (France)</td>
<td>Small, non-significant decline in incidence in 2008 compared with earlier sampling periods</td>
<td>No increase in incidence rates</td>
<td>Prescription data unavailable</td>
</tr>
<tr>
<td>3. Bikdeli et al</td>
<td>US</td>
<td>Medicare</td>
<td>Age &gt;65 Medicare beneficiaries</td>
<td>NA</td>
<td>262 658</td>
<td>Adjusted rates of hospital admission and 30-day and 1-year mortality</td>
<td>2007 (AHA)</td>
<td>Adjusted hospitalisation rate increased from 1999 to 2005 and then declined progressively to 2010</td>
<td>No change in declining trajectory</td>
<td>Prescription and bacteriological data unavailable</td>
</tr>
<tr>
<td>4. Pasquali et al</td>
<td>USA</td>
<td>Pediatric Health Information Systems (PHIS) database</td>
<td>Age &lt;18 from 37 PHIS-participating centres</td>
<td>&gt;5 million</td>
<td>1157</td>
<td>The rate of change in the annual number of IE hospitalisations over time</td>
<td>2007 (AHA)</td>
<td>Hospitalisations for IE declined progressively throughout study period</td>
<td>No change in declining trajectory</td>
<td>Prescription data unavailable</td>
</tr>
<tr>
<td>5. Dayer et al</td>
<td>UK</td>
<td>Hospital discharge episode statistics</td>
<td>All patients in English hospitals with a discharge diagnosis of ‘acute or subacute IE’</td>
<td>NA</td>
<td>19 804</td>
<td>Interrupted time series analysis, to investigate effect of antibiotic prophylaxis on the incidence of IE</td>
<td>2008 (NICE)</td>
<td>A consistent upward trend in population-corrected incidence of IE, with small but significant increase after 2008</td>
<td>Cases increased significantly above the projected historical trend</td>
<td>Reduction in antibiotic prescription after 2008. Bacteriological data unavailable</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Data source</th>
<th>Population</th>
<th>Cases of IE</th>
<th>Analysis</th>
<th>Date of guideline</th>
<th>IE incidence trends</th>
<th>Change in IE incidence after guideline change</th>
<th>Prescription and bacteriological data</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. DeSimone et al</td>
<td>USA</td>
<td>Endocarditis Registry at Mayo Clinic and Rochester Epidemiology Project</td>
<td>Olmsted County adults (≥18 years) with definite or possible IE caused by streptococcal viridans</td>
<td>27</td>
<td>Age-adjusted and sex-adjusted incidence rates standardised against the 2010 US white population</td>
<td>2007 (AHA)</td>
<td>Incidence of IE trended downward during the study period</td>
<td>No change in declining trajectory</td>
<td>Prescription data unavailable Only 16% of cases caused by streptococcus</td>
</tr>
<tr>
<td>7. Pant et al</td>
<td>USA</td>
<td>The Nationwide Inpatient Sample database</td>
<td>All patients discharged with acute and subacute bacterial endocarditis</td>
<td>NA</td>
<td>Interrupted time series analysis of IE incidence rates</td>
<td>2007 (AHA)</td>
<td>Steady increase in the incidence of IE hospitalisations from 2000 to 2011</td>
<td>No significant change in upward trend</td>
<td>Prescription data unavailable Increase in streptococcal IE cases after 2007</td>
</tr>
</tbody>
</table>

AHA, American Heart Association; IE, infective endocarditis; NICE, National Institute for Health and Care Excellence.

Table 3  Study quality by selected STROBE criteria

<table>
<thead>
<tr>
<th>STROBE checklist (paragraph number)</th>
<th>Study population: selection by age</th>
<th>Monitoring period: before/after guideline</th>
<th>Diagnostic criteria for IE</th>
<th>Bacteriological data reported</th>
<th>Antibiotic data reported</th>
<th>IE rate estimate adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Thornhill et al</td>
<td>Unselected: all UK patients</td>
<td>8/2 years, continuous monitoring Isolated, cross-sectional data collection 11/3 years</td>
<td>ICD-10 codes</td>
<td>Yes, but incomplete</td>
<td>Yes</td>
<td>Unadjusted only</td>
</tr>
<tr>
<td>2. Duval et al</td>
<td>Selected: adults ≥20 years from French region</td>
<td>8/3 years</td>
<td>ICD-9 codes</td>
<td>No</td>
<td>No</td>
<td>Adjusted for age and sex only</td>
</tr>
<tr>
<td>3. Bikdeli et al</td>
<td>Selected: adults ≥65 years</td>
<td>7/3 years</td>
<td>ICD-9 codes</td>
<td>Yes—selected ICD-9 codes</td>
<td>No</td>
<td>Unadjusted incidence only</td>
</tr>
<tr>
<td>4. Pasquali et al</td>
<td>Selected: children &lt;18 years</td>
<td>8/5 years continuous monitoring</td>
<td>ICD-10 codes</td>
<td>Yes—but incomplete</td>
<td>Yes</td>
<td>Adjusted for size of UK population only</td>
</tr>
<tr>
<td>5. Dayer et al</td>
<td>Unselected: all UK patients</td>
<td>8/6 years</td>
<td>Duke criteria</td>
<td>Yes—complete</td>
<td>No</td>
<td>Unadjusted incidence only</td>
</tr>
<tr>
<td>6. DeSimone et al</td>
<td>Selected: adults ≥18 years in Olmstest County</td>
<td>7/4 years</td>
<td>ICD-9 codes</td>
<td>Yes—selected ICD-9 codes</td>
<td>No</td>
<td>Unadjusted incidence only</td>
</tr>
<tr>
<td>7. Pant et al</td>
<td>Unselected patients</td>
<td>7/4 years</td>
<td>ICD-9 codes</td>
<td>Yes—selected ICD-9 codes</td>
<td>No</td>
<td>Unadjusted incidence only</td>
</tr>
</tbody>
</table>

IE, infective endocarditis.
in table 3. The table documents the broad range of data sources for the seven studies, with variable age criteria for the study populations and uncertain diagnostic ascertainment of IE in all but studies 2 and 6. Antibiotic prophylaxis rates were captured in only two studies and although bacteriological data were presented in all but one, it was often incomplete with inclusion of streptococcal viridans isola
tions rates in only two of them. Incidence rates for IE were reported in all the studies but although some adjusted for age and sex, plus ethnicity in one, and the size of the denominator population in another, other potentially relevant confounders, particularly time-dependent changes in baseline risk characteristics of the denominator populations, were unavailable for modelling purposes introducing considerable bias into the incidence estimates.

**DISCUSSION**

This systematic review identified seven observational studies that have provided estimates of IE diagnostic rates before-and-after changes to national guideline recommendations.16–22 The quality of the studies was variable but generally insufficient to resolve uncertainty about how these changes have affected rates of incident IE; one of the studies reporting a small rate increase, whereas the others reporting no significant change compared to the period antedating guideline changes. It is unlikely that further observational studies of incident IE before-and-after guideline changes will be helpful in resolving this uncertainty.

Population studies of sufficient quality to provide confident estimates of how antibiotic prophylaxis affects rates of incident IE have proved hard to prosecute. The relative rarity of IE demands huge populations to generate sufficient cases. Only an estimated 35–45% of such cases, however, are due to oral streptococcal infection and of these only a proportion, perhaps half, are likely to result from invasive dental procedures making them potentially preventable by antibiotic prophylaxis. Add to this the increasing prevalence of staphylococcal endocarditis in recent years and it is clear that studies of almost unprecedented scale would be required to confidently identify changes in rates of incident IE in response to the antibiotic guideline changes. Whether any of the studies included in this review were sufficiently large enough to answer this question, therefore, is questionable. Numbers were large in four studies from the UK and USA, but the registry sources in these studies are potentially subject to under-reporting and coding inconsistencies either of which may have distorted incidence estimates and trends over time.23 The remaining studies were considerably smaller and although diagnostic ascertainment was a strength in two of them, the limited number of cases inevitably undermines confidence in the incidence analyses. In many of the studies, patient selection by age, hospital type or geographic area questions their generalisability, and in all of them, incidence estimates are undermined by the unavailability of risk factor data and other confounders. Thus, while incidence estimates were adjusted for age and sex in three studies plus ethnicity in one and the size of the denominator population in another, none was able to adjust for population risk factors such as structural cardiac disorders, implanted intravascular devices, diabetes and immunosuppression. This has major potential to distort the calculated IE incidence trends given the relative rarity of IE and the increasing numbers of people at risk in western populations through aortic valve disease, adult congenital heart disease and immunodepressive disorders.24 25

In assessing the impact of guideline changes on incidence of IE, it should be recognised that the US and European guidelines10 11 continued to advise antibiotic prophylaxis for very high-risk patients (prosthetic heart valves or prior endocarditis), unlike the UK’s NICE.
guideline which was more radical in ruling out the need for antibiotic prophylaxis across all patient groups.\textsuperscript{12} It is instructive, therefore, to focus on the two studies from the UK because the impact of the 2008 guideline change was potentially greatest here.\textsuperscript{16,20} Despite similarities between the studies in terms of their national perspective, patient identification and data analysis, only the more recent study by Dayer et al.\textsuperscript{20} with three additional years of follow-up, found a small but significant increase in the incidence of IE above the projected historical trend following the NICE guideline change. This was associated with a sharp 90\% reduction in antibiotic prescriptions. There is no clear explanation for the disparate findings of the two UK studies but the Dayer paper has been criticised for including 2007 data in the postguideline analysis even though the guideline was not introduced until October that year.\textsuperscript{20} Moreover, a recent critique of the Dayer study in the NICE clinical guideline update concluded that the study, in particular the change in slope of the incidence curve, was at high risk of bias.\textsuperscript{27} Certainly, as the editorialist emphasised,\textsuperscript{28} the temporal association between reduced antibiotic prescriptions and increased rates of IE reported by Dayer et al.\textsuperscript{20} do not prove causality, not least because there was no adjustment for temporal changes in major risk factors for IE, including age, in the annual incidence calculations.

Although the studies included in this review sought to determine how guideline-recommended changes in antibiotic prophylaxis have affected incident IE, only the two UK studies reported prescription data. Without prescription data, it is simply not possible to determine whether temporal changes in incident IE have been influenced by changes in antibiotic prophylaxis called for in guidelines. For the two UK studies, it must be recognised that prescription data were not linked to the health records which, coupled with the unadjusted incidence calculations, makes it impossible to determine whether the sharp reduction in prescriptions following the 2009 NICE guideline was causally related to changes in incident IE. The monitored prescriptions for a single 3 g dose of oral amoxicillin (or a 600 mg dose of oral clindamycin for patients allergic to penicillin) account for the large bulk of prophylactic treatment in patients undergoing dental work and are targeted against streptococcal infection. Logically, therefore, any change consequent to the guideline recommendations should be confined largely to streptococcal IE. It was a limitation of the Dayer study\textsuperscript{20} that the infective organism was not available to the investigators and we do not know, therefore, if the small increase in the recorded incidence of IE after 2008 was driven by increases in streptococcal IE. The earlier UK study, however, found no apparent change in the upward trend of streptococcal IE after 2008, although the recording of infective organisms was incomplete and captured streptococcal infection generically without specification of the viridans species.\textsuperscript{16} Nevertheless, the French study, the smaller Olmstead County study and the US Children’s study\textsuperscript{17,19,21} also reported no increases in cases of streptococcal infection after the guideline changes. Only the large US study by Pant et al.\textsuperscript{22} reported an increase in streptococcal IE hospitalisation rates although overall trends in IE hospitalisations from 2000 to 2007 and from 2008 to 2011 were not significantly different.

The sharp fall in UK prophylactic antibiotic prescriptions in 2008 reflects a level of adherence to the guideline changes. This is consistent with the results of a survey in which 87\% of UK dentists reported adherence to the NICE guidance, although 35\% admitted administering antibiotic prophylaxis after the guideline change. Among cardiologists and cardiothoracic surgeons, only 61\% reported adherence.\textsuperscript{29} A more contemporary US survey of paediatric cardiologists found that more than half of the participants (56\%) do not follow current antibiotic prophylaxis guidelines.\textsuperscript{30} This variable, often low level of adherence, further limits the ability of the studies included in this review to provide reliable estimates of the impact of guideline changes on the incidence of IE.

Since this systematic review was completed, at least two further studies have been published aimed at determining the impact of antibiotic prophylaxis guideline changes on the incidence of IE.\textsuperscript{31,32} Similar limitations to those discussed in this review applied to both studies, one of which reported no impact of the guideline\textsuperscript{31} and the other a negative impact reflected in a significant increase in streptococci-related IE cases.\textsuperscript{32} Concerns that international guideline changes to recommendations for antibiotic prophylaxis in at-risk patients might lead to an increase in rates of IE have not been resolved by the observational studies included in this systematic review. The heterogeneity of the studies makes robust conclusions impossible particularly given their variable methodological limitations, including study size, duration of follow-up, diagnostic ascertainment, uncertainty about guideline adherence, and absence of relevant prescription and bacteriological data. Many of the studies suggested an upward trend in incident IE not obviously associated with the guideline changes and there is a clear need for onward monitoring. However, further before-and-after observational studies of the type included in this review will not be helpful in determining the impact of the antibiotic prophylaxis guideline changes without detailed clinical phenotyping of unselected registry populations at scale, with linked prescribing and bacteriological data.

\textbf{Contributors} OK contributed to project planning, literature searches, data interpretation and writing of the manuscript. AMAS contributed to literature searches and manuscript review. AT contributed to project planning, data interpretation and writing of the manuscript.

\textbf{Funding} AT acknowledges support of Barts and the London Cardiovascular Biomedical Research Unit, funded by the National Institute for Health Research.

\textbf{Competing interests} None declared.

\textbf{Provenance and peer review} Not commissioned; externally peer reviewed.
REFERENCES


